ARVINAS INC (ARVN) Stock Price, Forecast & Analysis
NASDAQ:ARVN • US04335A1051
ARVN Key Statistics, Chart & Performance
The current stock price of ARVN is 13.13 USD. In the past month the price increased by 0.07%. In the past year, price decreased by -26.75%.
ARVN Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ARVN. When comparing the yearly performance of all stocks, ARVN is a bad performer in the overall market: 79.86% of all stocks are doing better.
ARVN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ARVN. The financial health of ARVN is average, but there are quite some concerns on its profitability.
ARVN Financial Highlights
Over the last trailing twelve months ARVN reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS increased by 53.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.26% | ||
| ROE | -18.62% | ||
| Debt/Equity | 0 |
ARVN Forecast & Estimates
26 analysts have analysed ARVN and the average price target is 13.68 USD. This implies a price increase of 4.19% is expected in the next year compared to the current price of 13.13.
For the next year, analysts expect an EPS growth of -161.62% and a revenue growth -69.33% for ARVN
ARVN Ownership
ARVN Latest News, Press Relases and Analysis
ARVN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 29.86 | 962.369B | ||
| JNJ | JOHNSON & JOHNSON | 21.15 | 598.856B | ||
| MRK | MERCK & CO. INC. | 22.3 | 301.342B | ||
| PFE | PFIZER INC | 8.89 | 154.992B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 10.12 | 126.909B | ||
| ZTS | ZOETIS INC | 18.4 | 56.831B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.15 | 27.402B | ||
| VTRS | VIATRIS INC | 6 | 18.077B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.76 | 12.971B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.51B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ARVN
Company Profile
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 246 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Company Info
ARVINAS INC
5 Science Park
New Haven CONNECTICUT 06511 US
CEO: John Houston
Employees: 246
Phone: 13026365400
ARVINAS INC / ARVN FAQ
What does ARVINAS INC do?
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company is headquartered in New Haven, Connecticut and currently employs 246 full-time employees. The company went IPO on 2018-09-27. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. The company is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The company is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Can you provide the latest stock price for ARVINAS INC?
The current stock price of ARVN is 13.13 USD. The price decreased by -1.94% in the last trading session.
What is the dividend status of ARVINAS INC?
ARVN does not pay a dividend.
What is the ChartMill technical and fundamental rating of ARVN stock?
ARVN has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of ARVINAS INC (ARVN)?
ARVINAS INC (ARVN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).
What is ARVINAS INC worth?
ARVINAS INC (ARVN) has a market capitalization of 839.79M USD. This makes ARVN a Small Cap stock.